



Pharma Nord

Methodology Note

Supporting the Disclosure Report for Transfers of Value 2023

This report includes transfers of value processed by Pharma Nord (UK) Ltd during the reporting period for 2023.

Introduction

Pharma Nord (UK) Ltd are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. This methodological note outlines the process and procedures followed by Pharma Nord (UK) Ltd in disclosing transfers of value to HCPs and HCOs, as per the ABPI Code of Practice. Transparency in financial relationships between the pharmaceutical industry and healthcare professionals is essential to build trust and uphold the integrity of healthcare practices. The disclosure of transfers of value is in line with our commitment to ethical business practices and compliance with industry regulations.

Scope

This disclosure initiative encompasses all transfers of value made by Pharma Nord (UK) Ltd to healthcare professionals and healthcare organizations in the UK, as defined by the ABPI Code of Practice. Transfers of value include but are not limited to honoraria, travel and accommodation, registration fees, grants, donations, and sponsorships for educational events and conferences (as detailed in the Transfer of Value Categories section of this document).

Disclosures of transfers of value to patient organisations are not covered in this disclosure but are published on Pharma Nord (UK) Ltd's medical website.

In the reporting year 2023, Pharma Nord (UK) Ltd did not make any donations or grants, did not make any payments to HCPs, did not fund any registration fees/travel and accommodation, did not make any payments regarding research and development.

Transfer of Value Categories

Category	Subcategory	Example Activities
Contribution to Cost of Events	Sponsorship Agreements (HCOs only)	<ul style="list-style-type: none">Funding an event in return for a display booth

VAT

All disclosed transfer of value amounts will be reported as net amounts, excluding VAT.

Transfers of Value connected to groups of products which do not solely comprise prescription pharmaceuticals

Under the EFPIA disclosure code, transfers of value are only covered in connection with prescription-only medicines.

Where Pharma Nord (UK) Ltd's transfers of value are exclusively connected to our over-the-counter supplements, this will not be in scope of EFPIA disclosure code and will not be disclosed.

Where Pharma Nord (UK) Ltd's transfers of value are exclusively connected to our prescription medicines, this will be in scope of EFPIA disclosure code and will be disclosed.

Where Pharma Nord (UK) Ltd's transfers of value are connected to both our over-the-counter supplements and prescription medicines, this will be disclosed in full.

Verification and Accuracy

All disclosed information will be thoroughly reviewed and verified to ensure accuracy and compliance with EFPIA disclosure code and ABPI guidelines.

Regular internal audits will be conducted to validate the data accuracy and completeness.